Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022
“Parkinson’s disease treatment market projected to grow at a CAGR of 6.1%”
The Parkinson’s disease treatment market is expected to grow from USD 4.24 billion in 2017 to USD 5,694.1 million in 2022 to grow at a CAGR of 6.1%. Factors such as the increasing aging population worldwide and government funding for research on Parkinson’s disease are driving this market. However, the availability of alternative treatments is expected to restrain this market.
“The carbidopa/levodopa segment is expected to register the highest CAGR during the forecast period”
On the basis of drug class, the Parkinson’s disease treatment market is classified into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to register the highest growth rate during the forecast period. The growth of this market segment is mainly driven by its potency and wide adoption in the treatment of Parkinson’s disease.
“The online pharmacies segment to grow at the fastest rate during the forecast period”
By distribution channel type, the Parkinson’s disease treatment market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. The online pharmacies segment is expected to register highest CAGR during the forecast period. Advantages such as 24/7 ordering, home delivery, and discounts on medicines are the driving factors for this segment.
“Europe to hold the largest share of the regional market during the forecast period”
Geographically, the Parkinson’s disease treatment market is dominated by Europe, followed by North America, Asia, and the Rest of the World (RoW). Europe is expected to command the largest share of the Parkinson’s disease treatment market. The large share of this segment can be attributed to the growing aging population, presence of key players, and increasing healthcare expenditure in the region. The Asian region is estimated to grow at the fastest rate during the forecast period.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage:
The report analyses the Parkinson’s disease treatment market by drug class, distribution channel, patient care setting, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides the competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the report analyses developments and strategies adopted by key players to maintain and increase their shares in the market. The above-mentioned market research data, market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions to be successful in the market.
Benefits of Buying this Report:
This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.
The report provides insights on the following strategies:
The Parkinson’s disease treatment market is expected to grow from USD 4.24 billion in 2017 to USD 5,694.1 million in 2022 to grow at a CAGR of 6.1%. Factors such as the increasing aging population worldwide and government funding for research on Parkinson’s disease are driving this market. However, the availability of alternative treatments is expected to restrain this market.
“The carbidopa/levodopa segment is expected to register the highest CAGR during the forecast period”
On the basis of drug class, the Parkinson’s disease treatment market is classified into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to register the highest growth rate during the forecast period. The growth of this market segment is mainly driven by its potency and wide adoption in the treatment of Parkinson’s disease.
“The online pharmacies segment to grow at the fastest rate during the forecast period”
By distribution channel type, the Parkinson’s disease treatment market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. The online pharmacies segment is expected to register highest CAGR during the forecast period. Advantages such as 24/7 ordering, home delivery, and discounts on medicines are the driving factors for this segment.
“Europe to hold the largest share of the regional market during the forecast period”
Geographically, the Parkinson’s disease treatment market is dominated by Europe, followed by North America, Asia, and the Rest of the World (RoW). Europe is expected to command the largest share of the Parkinson’s disease treatment market. The large share of this segment can be attributed to the growing aging population, presence of key players, and increasing healthcare expenditure in the region. The Asian region is estimated to grow at the fastest rate during the forecast period.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type - Tier 1 – 70% and Tier 2 – 30%
- By Designation – C-level – 62%, Director Level – 21%, Others – 17%
- By Region – North America – 50%, Europe – 20%, Asia – 30%
Research Coverage:
The report analyses the Parkinson’s disease treatment market by drug class, distribution channel, patient care setting, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides the competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the report analyses developments and strategies adopted by key players to maintain and increase their shares in the market. The above-mentioned market research data, market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions to be successful in the market.
Benefits of Buying this Report:
This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.
The report provides insights on the following strategies:
- Market Penetration: The report analyzes the Parkinson’s disease treatment market by drug class, distribution channel, and patient care setting
- Competitive Assessment: In-depth assessment of the market strategies and geographic and business segments of the leading players in the Parkinson’s disease treatment market
- Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various drug classes across geographies
- Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the Parkinson’s disease treatment market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PARKINSON’S DISEASE TREATMENT MARKET OVERVIEW
4.2 GEOGRAPHIC ANALYSIS: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS
4.3 GEOGRAPHIC ANALYSIS OF THE PARKINSON’S DISEASE TREATMENT MARKET, BY COUNTRY
4.4 GEOGRAPHIC ANALYSIS OF THE PARKINSON’S DISEASE TREATMENT MARKET
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growth in aging population and the associated increase in the prevalence of Parkinson’s disease
5.2.1.2 Government funding for research
5.2.2 RESTRAINTS
5.2.2.1 Availability of alternative treatments
5.2.3 OPPORTUNITIES
5.2.3.1 Patent expiry of branded drugs
5.2.3.2 Strong drug pipeline
6 PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS
6.1 INTRODUCTION
6.2 CARBIDOPA/LEVODOPA
6.3 DOPAMINE RECEPTOR AGONISTS
6.4 MAO INHIBITORS
6.5 COMT INHIBITORS
6.6 ANTICHOLINERGICS
6.7 OTHER DRUGS
7 PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
7.1 INTRODUCTION
7.2 HOSPITAL PHARMACIES
7.3 RETAILER PHARMACIES
7.4 ONLINE PHARMACIES
8 PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING
8.1 INTRODUCTION
8.2 HOSPITALS
8.3 CLINICS
9 PARKINSON’S DISEASE TREATMENT MARKET, BY REGION
9.1 INTRODUCTION
9.2 EUROPE
9.3 NORTH AMERICA
9.3.1 U.S.
9.3.2 CANADA
9.4 ASIA
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 REST OF ASIA
9.5 REST OF THE WORLD
10 COMPANY PROFILES
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
10.1 GSK
10.2 MERCK
10.3 NOVARTIS
10.4 TEVA
10.5 BOEHRINGER INGELHEIM
10.6 IMPAX
10.7 ABBVIE
10.8 VALEANT PHARMACEUTICALS
10.9 LUNDBECK
10.10 SUN PHARMA
10.11 WOCKHARDT
10.12 ACADIA
10.13 UCB
*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.
11 APPENDIX
11.1 INSIGHTS OF INDUSTRY EXPERTS
11.2 DISCUSSION GUIDE
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
11.5 AVAILABLE CUSTOMIZATIONS
11.6 RELATED REPORTS
11.7 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PARKINSON’S DISEASE TREATMENT MARKET OVERVIEW
4.2 GEOGRAPHIC ANALYSIS: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS
4.3 GEOGRAPHIC ANALYSIS OF THE PARKINSON’S DISEASE TREATMENT MARKET, BY COUNTRY
4.4 GEOGRAPHIC ANALYSIS OF THE PARKINSON’S DISEASE TREATMENT MARKET
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growth in aging population and the associated increase in the prevalence of Parkinson’s disease
5.2.1.2 Government funding for research
5.2.2 RESTRAINTS
5.2.2.1 Availability of alternative treatments
5.2.3 OPPORTUNITIES
5.2.3.1 Patent expiry of branded drugs
5.2.3.2 Strong drug pipeline
6 PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS
6.1 INTRODUCTION
6.2 CARBIDOPA/LEVODOPA
6.3 DOPAMINE RECEPTOR AGONISTS
6.4 MAO INHIBITORS
6.5 COMT INHIBITORS
6.6 ANTICHOLINERGICS
6.7 OTHER DRUGS
7 PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
7.1 INTRODUCTION
7.2 HOSPITAL PHARMACIES
7.3 RETAILER PHARMACIES
7.4 ONLINE PHARMACIES
8 PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING
8.1 INTRODUCTION
8.2 HOSPITALS
8.3 CLINICS
9 PARKINSON’S DISEASE TREATMENT MARKET, BY REGION
9.1 INTRODUCTION
9.2 EUROPE
9.3 NORTH AMERICA
9.3.1 U.S.
9.3.2 CANADA
9.4 ASIA
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 REST OF ASIA
9.5 REST OF THE WORLD
10 COMPANY PROFILES
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
10.1 GSK
10.2 MERCK
10.3 NOVARTIS
10.4 TEVA
10.5 BOEHRINGER INGELHEIM
10.6 IMPAX
10.7 ABBVIE
10.8 VALEANT PHARMACEUTICALS
10.9 LUNDBECK
10.10 SUN PHARMA
10.11 WOCKHARDT
10.12 ACADIA
10.13 UCB
*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.
11 APPENDIX
11.1 INSIGHTS OF INDUSTRY EXPERTS
11.2 DISCUSSION GUIDE
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
11.5 AVAILABLE CUSTOMIZATIONS
11.6 RELATED REPORTS
11.7 AUTHOR DETAILS
LIST OF TABLES
Table 1 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET SUMMARY
Table 2 AGEING POPULATION, BY REGION, 2015 VS 2030
Table 3 PARKINSON’S DISEASE TREATMENT MARKET: LIST OF PIPELINE DRUGS
Table 4 PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2016–2022 (USD MILLION)
Table 5 CARBIDOPA/LEVODOPA MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 6 NORTH AMERICA: CARBIDOPA/LEVODOPA MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 7 ASIA: CARBIDOPA/LEVODOPA MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 8 DOPAMINE RECEPTOR AGONISTS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 9 NORTH AMERICA: DOPAMINE RECEPTOR AGONISTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 10 ASIA: DOPAMINE RECEPTOR AGONISTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 11 MAO INHIBITORS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 12 NORTH AMERICA: MAO INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 13 ASIA: MAO INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 14 COMT INHIBITORS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 15 NORTH AMERICA: COMT INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 16 ASIA: COMT INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 17 ANTICHOLINERGICS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 18 NORTH AMERICA: ANTICHOLINERGICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 19 ASIA: ANTICHOLINERGICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 20 OTHER DRUGS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 21 NORTH AMERICA: OTHER DRUGS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 22 ASIA: OTHER DRUGS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 23 PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 24 PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2015–2022 (USD MILLION)
Table 25 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 26 PARKINSON’S DISEASE TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2015–2022 (USD MILLION)
Table 27 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR RETAILER PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 28 PARKINSON’S DISEASE TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2015–2022 (USD MILLION)
Table 29 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 30 PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 31 PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY REGION, 2015–2022 (USD MILLION)
Table 32 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 33 ASIA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 34 PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS, BY REGION, 2015–2022 (USD MILLION)
Table 35 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 36 ASIA: PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 37 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 38 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 39 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 40 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 41 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 42 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 43 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 44 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 45 US: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 46 US: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 47 US: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 48 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 49 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 50 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 51 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 52 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 53 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 54 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 55 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 56 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 57 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 58 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 59 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 60 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 61 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 62 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 63 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 64 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 65 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 66 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 1 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET SUMMARY
Table 2 AGEING POPULATION, BY REGION, 2015 VS 2030
Table 3 PARKINSON’S DISEASE TREATMENT MARKET: LIST OF PIPELINE DRUGS
Table 4 PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2016–2022 (USD MILLION)
Table 5 CARBIDOPA/LEVODOPA MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 6 NORTH AMERICA: CARBIDOPA/LEVODOPA MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 7 ASIA: CARBIDOPA/LEVODOPA MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 8 DOPAMINE RECEPTOR AGONISTS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 9 NORTH AMERICA: DOPAMINE RECEPTOR AGONISTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 10 ASIA: DOPAMINE RECEPTOR AGONISTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 11 MAO INHIBITORS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 12 NORTH AMERICA: MAO INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 13 ASIA: MAO INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 14 COMT INHIBITORS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 15 NORTH AMERICA: COMT INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 16 ASIA: COMT INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 17 ANTICHOLINERGICS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 18 NORTH AMERICA: ANTICHOLINERGICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 19 ASIA: ANTICHOLINERGICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 20 OTHER DRUGS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 21 NORTH AMERICA: OTHER DRUGS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 22 ASIA: OTHER DRUGS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 23 PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 24 PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2015–2022 (USD MILLION)
Table 25 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 26 PARKINSON’S DISEASE TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2015–2022 (USD MILLION)
Table 27 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR RETAILER PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 28 PARKINSON’S DISEASE TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2015–2022 (USD MILLION)
Table 29 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 30 PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 31 PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY REGION, 2015–2022 (USD MILLION)
Table 32 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 33 ASIA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 34 PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS, BY REGION, 2015–2022 (USD MILLION)
Table 35 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 36 ASIA: PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 37 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 38 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 39 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 40 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 41 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 42 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 43 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 44 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 45 US: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 46 US: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 47 US: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 48 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 49 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 50 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 51 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 52 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 53 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 54 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 55 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 56 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 57 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 58 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 59 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 60 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 61 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 62 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 63 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
Table 64 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015–2022 (USD MILLION)
Table 65 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION)
Table 66 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION)
LIST OF FIGURES
Figure 1 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET
Figure 2 RESEARCH DESIGN
Figure 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 4 PARKINSON’S DISEASE TREATMENT MARKET: BOTTOM-UP APPROACH
Figure 5 PARKINSON’S DISEASE TREATMENT MARKET: TOP-DOWN APPROACH
Figure 6 DATA TRIANGULATION METHODOLOGY
Figure 7 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2017 VS. 2022
Figure 8 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017 VS. 2022
Figure 9 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2017 VS. 2022
Figure 10 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY REGION, 2017 VS. 2022
Figure 11 INCREASING PREVALENCE OF PARKINSON’S DISEASE TO DRIVE THE GROWTH OF THE PARKINSON’S DISEASE TREATMENT MARKET
Figure 12 CARBIDOPA/LEVODOPA SEGMENT AND JAPAN TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017
Figure 13 JAPAN TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 14 EUROPE TO REGISTER THE HIGHEST MARKEST SHARE DURING THE FORECAST PERIOD
Figure 15 PARKINSON’S DISEASE TREATMENT MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
Figure 16 HOSPITAL PHARMACIES TO CONTINUE TO DOMINATE THE PARKINSON’S DISEASE TREATMENT MARKET DURING THE FORECAST PERIOD
Figure 17 HOSPITALS SEGMENT TO DOMINATE THE PARKINSON’S DISEASE TREATMENT MARKET DURING THE FORECAST PERIOD
Figure 18 PARKINSON’S DISEASE TREATMENT MARKET: GEOGRAPHIC SNAPSHOT (2017-2022)
Figure 19 NORTH AMERICA: MARKET SNAPSHOT
Figure 20 ASIA: MARKET SNAPSHOT
Figure 21 GSK .: COMPANY SNAPSHOT
Figure 22 MERCK: COMPANY SNAPSHOT
Figure 23 NOVARTIS: COMPANY SNAPSHOT
Figure 24 TEVA: COMPANY SNAPSHOT
Figure 25 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
Figure 26 IMPAX: COMPANY SNAPSHOT
Figure 27 ABBVIE.: COMPANY SNAPSHOT
Figure 28 VALEANT: COMPANY SNAPSHOT
Figure 29 LUNDBECK: COMPANY SNAPSHOT
Figure 30 SUN PHARMA: COMPANY SNAPSHOT
Figure 31 WOCKHARDT: COMPANY SNAPSHOT
Figure 32 ACADIA.: COMPANY SNAPSHOT
Figure 33 UCB: COMPANY SNAPSHOT
Figure 1 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET
Figure 2 RESEARCH DESIGN
Figure 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 4 PARKINSON’S DISEASE TREATMENT MARKET: BOTTOM-UP APPROACH
Figure 5 PARKINSON’S DISEASE TREATMENT MARKET: TOP-DOWN APPROACH
Figure 6 DATA TRIANGULATION METHODOLOGY
Figure 7 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2017 VS. 2022
Figure 8 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017 VS. 2022
Figure 9 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2017 VS. 2022
Figure 10 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY REGION, 2017 VS. 2022
Figure 11 INCREASING PREVALENCE OF PARKINSON’S DISEASE TO DRIVE THE GROWTH OF THE PARKINSON’S DISEASE TREATMENT MARKET
Figure 12 CARBIDOPA/LEVODOPA SEGMENT AND JAPAN TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017
Figure 13 JAPAN TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 14 EUROPE TO REGISTER THE HIGHEST MARKEST SHARE DURING THE FORECAST PERIOD
Figure 15 PARKINSON’S DISEASE TREATMENT MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
Figure 16 HOSPITAL PHARMACIES TO CONTINUE TO DOMINATE THE PARKINSON’S DISEASE TREATMENT MARKET DURING THE FORECAST PERIOD
Figure 17 HOSPITALS SEGMENT TO DOMINATE THE PARKINSON’S DISEASE TREATMENT MARKET DURING THE FORECAST PERIOD
Figure 18 PARKINSON’S DISEASE TREATMENT MARKET: GEOGRAPHIC SNAPSHOT (2017-2022)
Figure 19 NORTH AMERICA: MARKET SNAPSHOT
Figure 20 ASIA: MARKET SNAPSHOT
Figure 21 GSK .: COMPANY SNAPSHOT
Figure 22 MERCK: COMPANY SNAPSHOT
Figure 23 NOVARTIS: COMPANY SNAPSHOT
Figure 24 TEVA: COMPANY SNAPSHOT
Figure 25 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
Figure 26 IMPAX: COMPANY SNAPSHOT
Figure 27 ABBVIE.: COMPANY SNAPSHOT
Figure 28 VALEANT: COMPANY SNAPSHOT
Figure 29 LUNDBECK: COMPANY SNAPSHOT
Figure 30 SUN PHARMA: COMPANY SNAPSHOT
Figure 31 WOCKHARDT: COMPANY SNAPSHOT
Figure 32 ACADIA.: COMPANY SNAPSHOT
Figure 33 UCB: COMPANY SNAPSHOT
